We are focusing on strategies to deliver therapeutics via in vivo delivery of gene transfer vectors to generate ectopic “protein factories” capable of secreting therapeutic proteins into both the lung lumen and the systemic circulation. These approaches aim to provide an increased quality of life and a decreased treatment cost for a range of lung diseases, endocrine diseases and inborn errors of metabolism. The protein factories are established using conventional gene therapy or applying in vivo gene editing to correct defective loci and enable therapeutic protein expression.
Protein based therapeutics, once a rarely used subset of medical treatments, are now widely adopted with over 130 different proteins/peptides approved for clinical use. Hormone and enzyme replacement therapies have had dramatic clinical impact in chronic diseases such as cystic fibrosis, diabetes and the lysosomal storage disorders (LSDs) Pompe and Gauchers disease. However these therapies can be associated with high treatment burdens (e.g. multiple daily inhalations or injections) and extremely high treatment costs (e.g. $200-700K per year for LSDs).
We achieve efficient liver and muscle gene delivery using recombinant adeno-associated virus (rAAV) vectors, while our preferred lung gene delivery approach is a novel, patent protected, third-generation, self-inactivating simian immunodeficiency virus in which the envelope proteins have been replaced with the F & HN proteins from Sendai virus (rSIV.F/HN) to increase airway cell targeting. Delivery of thsese vectors to the appropriate organs results in abundant and long-lived expression of transgenes: for example, therapeutic monoclonal antibodies can be expressed for the lifetime of experimental animals. This project will utilise our experience of in vivo gene transfer and/or in vivo gene editing to understand and manipulate the factors required for effective expression and secretion of therapeutic proteins. Outcomes such as metabolic, haemostatic, muscle and cardio-respiratory function will be evaluated in human cell culture and knockout/genome engineered mouse models while preparing to translate promising approaches to early phase clinical studies.
Students will be exposed to many aspects of the translation of gene therapy research, including vector design and production, and the development of assays for correction of gene defects. In addition to cell and molecular biology, the student will receive training in gene editing, microscopy & in vivo imaging, protein characterisation along with virus production/purification and functional evaluation, PCR, FACS, Western blotting, immunocytochemistry, ELISA, quantitative (RT)-PCR, lentivirus production, & Tangential Flow Filtration (TFF) methods.
As well as the specific training detailed above, students will have access to high-quality training in scientific and generic skills, as well as access to a wide-range of seminars and training opportunities through the many research institutes and centres based in Oxford.
The Department has a successful mentoring scheme, open to graduate students, which provides an additional possible channel for personal and professional development outside the regular supervisory framework. We hold an Athena SWAN Silver Award in recognition of our efforts to build a happy and rewarding environment where all staff and students are supported to achieve their full potential.
Our main deadline for applications for funded places has now passed. Supervisors may still be able to consider applications from students who have alternative means of funding (for example, charitable funding, clinical fellows or applicants with funding from a foreign government or equivalent). Prospective applicants are strongly advised to contact their prospective supervisor in advance of making an application.
Please note that any applications received after the main funding deadline will not be assessed until all applications that were received by the deadline have been processed. This may affect supervisor availability.
Paul-Smith MC, et al (2018). The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins. Gene Therapy. 2018 Aug;25(5):345-358. https://www.ncbi.nlm.nih.gov/pubmed/30022127
Alton EW, et al (2017). Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax, Feb;72(2):137-147.https://www.ncbi.nlm.nih.gov/pubmed/27852956
How good is research at University of Oxford in Clinical Medicine?
FTE Category A staff submitted: 238.51
Research output data provided by the Research Excellence Framework (REF)
Click here to see the results for all UK universities